← All drugs
Drug · FAERS side-effect profile with label screen

Segesterone and Ethinyl Estradiol side effects: what 1 FDA adverse event reports show

Segesterone Acetate And Ethinyl Estradiol · 10 reaction terms · 112 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

No validated FDA label found

Who reports

1 reports · 100% serious · 0 with death outcome · 0% female

openFDA FAERS counts, all years, deduplication not applied

Used for

—

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 7 strongest signals

Reporting / coding artifact 1No label text to screen 6
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 3 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Vaginal discharge17101.0
63.5–160.6ROR 106.0 · χ² 1,582 / p <1e-300
90.8 EB05 60.1 · IC025 +3.9
3/3 methods agree
No label text to screen–no trial data cached
Vaginal haemorrhage3346.2
33.4–63.9ROR 50.9 · χ² 1,416 / p <1e-300
45.1 EB05 33.6 · IC025 +4.2
3/3 methods agree
No label text to screen–no trial data cached
Dysmenorrhoea1045.6
24.7–84.0ROR 46.9 · χ² 393 / p 1e-87
42.2 EB05 24.5 · IC025 +2.8
3/3 methods agree
No label text to screen–no trial data cached
Metrorrhagia1241.4
23.7–72.1ROR 42.8 · χ² 433 / p 2e-96
39.0 EB05 23.8 · IC025 +3.0
3/3 methods agree
No label text to screen–no trial data cached
Menstruation irregular920.2
10.6–38.5ROR 20.7 · χ² 146 / p 7e-34
18.7 EB05 9.4 · IC025 +2.2
3/3 methods agree
No label text to screen–no trial data cached
Amenorrhoea (missed periods)517.8
7.5–42.6ROR 18.1 · χ² 64 / p 8e-16
13.4 EB05 4.4 · IC025 +1.3
3/3 methods agree
No label text to screen–no trial data cached
Device expulsion1412.8
7.7–21.4ROR 13.3 · χ² 141 / p 8e-33
11.5 EB05 6.6 · IC025 +2.3
3/3 methods agree
Reporting / coding artifact–no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Vaginal haemorrhage3346.2
33.4–63.9ROR 50.9 · χ² 1,416 / p <1e-300
45.1 EB05 33.6 · IC025 +4.2
3/3 methods agree
No label text to screen–no trial data cached
Vaginal discharge17101.0
63.5–160.6ROR 106.0 · χ² 1,582 / p <1e-300
90.8 EB05 60.1 · IC025 +3.9
3/3 methods agree
No label text to screen–no trial data cached
Device expulsion1412.8
7.7–21.4ROR 13.3 · χ² 141 / p 8e-33
11.5 EB05 6.6 · IC025 +2.3
3/3 methods agree
Reporting / coding artifact–no trial data cached
Metrorrhagia1241.4
23.7–72.1ROR 42.8 · χ² 433 / p 2e-96
39.0 EB05 23.8 · IC025 +3.0
3/3 methods agree
No label text to screen–no trial data cached
Dysmenorrhoea1045.6
24.7–84.0ROR 46.9 · χ² 393 / p 1e-87
42.2 EB05 24.5 · IC025 +2.8
3/3 methods agree
No label text to screen–no trial data cached
Menstruation irregular920.2
10.6–38.5ROR 20.7 · χ² 146 / p 7e-34
18.7 EB05 9.4 · IC025 +2.2
3/3 methods agree
No label text to screen–no trial data cached
Amenorrhoea (missed periods)517.8
7.5–42.6ROR 18.1 · χ² 64 / p 8e-16
13.4 EB05 4.4 · IC025 +1.3
3/3 methods agree
No label text to screen–no trial data cached
Device difficult to use43.6
1.4–9.6ROR 3.6 · χ² 5 / p 0.012
2.8 EB05 1.2 · IC025 -0.3
PRR-only: not supported by EBGM or IC
Reporting / coding artifact–no trial data cached
Device defective414.7
5.6–39.0ROR 14.9 · χ² 38 / p 3e-10
9.1 EB05 2.9 · IC025 +0.8
3/3 methods agree
Reporting / coding artifact–no trial data cached
Libido decreased (lower sex drive)419.2
7.3–51.0ROR 19.4 · χ² 52 / p 3e-13
13.2 EB05 3.7 · IC025 +0.9
3/3 methods agree
No label text to screen–no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Medroxyprogesterone acetate ↔ Meningioma.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Segesterone and Ethinyl Estradiol?

In FDA FAERS, the most frequently co-reported reaction terms for Segesterone and Ethinyl Estradiol are vaginal haemorrhage, vaginal discharge, metrorrhagia, dysmenorrhoea, menstruation irregular, amenorrhoea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Segesterone and Ethinyl Estradiol have an FDA boxed warning?

No validated FDA label could be retrieved for this product name, so this page cannot say.

Do FAERS signals prove that Segesterone and Ethinyl Estradiol causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.